Daiichi Sankyo to pay $41.8M to Seagen in Enhertu patent case: Texas court enters judgment
gorodenkoff


Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) said a U.S. District Court entered judgment on a jury verdict finding that the company and AstraZeneca's (NASDAQ:AZN) drug Enhertu infringed Seagen's (NASDAQ:SGEN) U.S. patent willfully and awarded Seagen $41.8M in damages.
Daiichi added that despite the jury's finding of willfulness, regarding the U.S. Patent 10,808,039, the U.S. District Court for the Eastern District of Texas decided that under the circumstances an increase of damages was not warranted, and did not enhance the damages award.

Japan-based Daiichi noted that it will explore available post-trial motions and remedies to contest the judgment and damages awarded to Seagen.
The company said the court has not yet addressed whether to award a running royalty on future sales of the breast cancer drug until the expiry of the '039 patent in 2024.
Daiichi added that any impact on its financials for fiscal year ending March 31, 2023 was being evaluated and will be announced as soon as possible.